News & Insights
- 23/07/25 LEO Pharma Announces FDA Approval of ANZUPGO® (delgocitinib) Cream in the U.S.
- 14/07/25 Boehringer Ingelheim and LEO Pharma enter partnership to commercialize and further develop SPEVIGO® (spesolimab)
- 09/07/25 LEO Pharma Announces Positive 16-Week Interim Results for ADHAND Trial for Tralokinumab in Patients with Moderate-to-Severe Atopic Dermatitis on the Hands who are Candidates for Systemic Therapy
Our performance and results
Images
Useful information
- Fact sheet
A concise summary of LEO Pharma’s key information and achievements. Expect clear, straightforward data and essential insights. - Global Leadership Team
Get to know our top management team, featuring their expertise, accomplishments, and pivotal roles in driving LEO Pharma's success.
Our press releases are intended for the media
To comply with applicable regulation, product-related press releases are removed from our website within three weeks of publication. They are available upon request.. For updated information about clinical trials, please visit https://clinicaltrials.gov/ https://clinicaltrials.gov/.
About LEO Pharma
LEO Pharma is a global leader in medical dermatology. We deliver innovative solutions for skin health, building on a century of experience with breakthrough medicines in healthcare. We are committed to making a fundamental difference in people’s lives, and our broad portfolio of treatments serves close to 100 million patients in over 70 countries annually. Headquartered in Denmark, LEO Pharma has a team of 4,000 people worldwide. LEO Pharma is co-owned by majority shareholder the LEO Foundation and, since 2021, Nordic Capital. For more information, visit www.leo-pharma.com
